National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Gilteritinib (Xospata®)  as monotherapy is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation.

NCPE Assessment Process Complete
Rapid Review commissioned 14/10/2019
Rapid Review completed 29/11/2019
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of gilteritinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 02/12/2019
Pre-submission consultation with Applicant 03/02/2020
Current status Awaiting HTA submission from Applicant